Many Parkinson’s sufferers are waiting patiently for the expected mid-2025 results of a Norwegian clinical trial studying NAD+ boosting vitamin supplement Nicotinamide Riboside “NR” (FAQs) (Anecdotes). The trial’s chief investigator commented on the trial in a mid-December interview with Vogue Magazine:

Excerpts from Vogue Magazine:

“Scientists and doctors who study neurological disorders are particularly interested in what increasing NAD+ levels might do for their patients.

Charalampos Tzoulis, MD, professor of neurology and neurogenetics at the University of Bergen and Haukeland University Hospital in Norway, runs a center that tests new treatments for diseases like Parkinson’s.

After administering a megadose of one of the NAD+ precursors (NR), Tzoulis and his team were able to show, among a small sample of patients with Parkinson’s, increased NAD+ levels in the brain, a durable metabolic response, and a “small, but significant” clinical improvement in symptoms.

“And it was safe,” Tzoulis continues. “With no side effects.”

He has since enrolled 400 patients in a more extensive follow-up trial, with results expected in June.

If it works, he adds, “that will be big.”

As Tzoulis cautions, though, dozens of promising interventions have failed in the past.

Neurological disorders, aging in general—they’re thorny processes to disrupt.

…If his current trial demonstrates that NAD+ is a viable treatment option for Parkinson’s patients, he’ll move on to researching whether it can help prevent the disease.

After that, he’ll investigate whether the general smoothie-imbibing population stands to benefit from supplementation”

Related:

FOLLOW us on Twitter @RaisingNAD